Pharmacoeconomics of empirical antifungal use in febrile neutropenic hematological malignancy and hematopoietic stem cell transplant patients

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 13, Issue 2, 2013, Pages 227-235

  Turner, Stuart J ^a   Chen, Sharon C A ^b   Slavin, Monica A ^c   Kong, David C M ^d  

^a UNIVERSITY AT BUFFALO   (United States)

^b WESTMEAD HOSPITAL   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

antifungal; caspofungin; cost; empiric therapy; febrile neutropenia; invasive fungal infection; liposomal amphotericin B; pharmacoeconomics; voriconazole

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

CHILL; CLINICAL EFFECTIVENESS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEBRILE NEUTROPENIA; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION COST; HUMAN; LIVER DISEASE; LOW DRUG DOSE; NAUSEA; NEPHROTOXICITY; OUTCOME ASSESSMENT; QUALITY OF LIFE; REVIEW; SKIN MANIFESTATION; SURVIVAL TIME; SYSTEMIC MYCOSIS; VISUAL HALLUCINATION;

ANTIFUNGAL AGENTS; DECISION MAKING; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; FEVER; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOSES; NEUTROPENIA; TIME FACTORS;

EID: 84876149681     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.13.3     Document Type: Review

References (60)

1. Nivoix Y, Velten M, Letscher-Bru V et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin. Infect. Dis. 47(9), 1176-1184 (2008
2. Kurosawa M, Yonezumi M, Hashino S et al. Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int. J. Hematol. 96(6), 748-757 (2012
3. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: Outcomes and prognostic factors associated with mortality. Clin. Infect. Dis. 44(4), 531-540 (2007
4. Pagano L, Caira M, Candoni A et al. The epidemiology of fungal infections in patients with hematologic malignancies: The SEIFEM-2004 study. Haematologica 91(8), 1068-1075 (2006
5. Pagano L, Caira M, Nosari A et al. Fungal infections in recipients of hematopoieticview stem cell transplants: Results of the SEIFEM B-2004 study- Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin. Infect. Dis. 45(9), 1161-1170 (2007
6. Neofytos D, Horn D, Anaissie E et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: Analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin. Infect. Dis. 48(3), 265-273 (2009
7. Slavin M, Fastenau J, Sukarom I, Mavros P, Crowley S, Gerth WC. Burden of hospitalization of patients with Candida and Aspergillus infections in Australia. Int. J. Infect. Dis. 8(2), 111-120 (2004
8. Walsh TJ, Pappas P, Winston DJ et al.; National Institute of Allergy and Infectious Diseases Mycoses Study Group. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med. 346(4), 225-234 (2002
9. Rüping MJ, Vehreschild JJ, Cornely OA. Patients at high risk of invasive fungal infections: When and how to treat. Drugs 68(14), 1941-1962 (2008
10. Kriengkauykiat J, Ito JI, Dadwal SS. Epidemiology and treatment approaches in management of invasive fungal infections. Clin. Epidemiol. 3, 175-191 (2011
11. McCormack PL, Perry CM. Caspofungin: A review of its use in the treatment of fungal infections. Drugs 65(14), 2049-2068 (2005
12. Bow EJ. Neutropenic fever syndromes in patients undergoing cytotoxic therapy for acute leukemia and myelodysplastic syndromes. Semin. Hematol. 46(3), 259-268 (2009
13. Zaragoza R, Pemán J, Salavert M et al. Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts? Ther. Clin. Risk Manag. 4(6), 1261-1280 (2008
14. Marchetti O, Cordonnier C, Calandra T. Empirical antifungal therapy in neutropaenic cancer patients with persistent fever. EJC Suppl. 5, 32-42 (2007
15. Freifeld AG, Bow EJ, Sepkowitz KA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 52(4), e56-e93 (2011
16. Ferrara JJ, MacDougall C, Gallagher JC. Empiric antifungal therapy in patients with febrile neutropenia. Pharmacotherapy 31(4), 369-385 (2011
17. Rüping MJ, Vehreschild JJ, Groll A et al. Current issues in the clinical management of invasive aspergillosis- the AGIHO, DMykG, ÖGMM and PEG web-based survey and expert consensus conference 2009. Mycoses 54(5), e557-e568 (2011
18. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 351(14), 1391-1402 (2004
19. Oakley KL, Moore CB, Denning DW. In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. J. Antimicrob. Chemother. 42(1), 91-94 (1998
20. Tabosa Do Egito E, Appel M, Fessi H, Barratt G, Puisieux F, Devissaguet J-P. In-vitro and in-vivo evaluation of a new amphotericin B emulsion-based delivery system. J. Antimicrob. Chemother. 38(3), 485-497 (1996
21. Földi R, Kovács R, Gesztelyi R et al. Comparison of in vitro and vivo efficacy of caspofungin against Candida parapsilosis, C. orthopsilosis, C. metapsilosis and C. albicans. Mycopathologia 174(4), 311-318 (2012
22. Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N. Engl. J. Med. 340(10), 764-771 (1999
23. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A; L Amph/ ABLC Collaborative Study Group. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin. Infect. Dis. 31(5), 1155-1163 (2000
24. Boogaerts M, Winston DJ, Bow EJ et al.; Itraconazole Neutropenia Study Group. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann. Intern. Med. 135(6), 412-422 (2001
25. Schuler U, Bammer S, Aulitzky WE et al. Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy. Onkologie 30(4), 185-191 (2007
26. Brielmaier BD, Casabar E, Kurtzeborn CM, McKinnon PS, Ritchie DJ. Early clinical experience with anidulafungin at a large tertiary care medical center. Pharmacotherapy 28(1), 64-73 (2008
27. Kubiak DW, Bryar JM, McDonnell AM et al. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: A retrospective, observational, sequential cohort analysis. Clin. Ther. 32(4), 637-648 (2010
28. Maertens J, Marchetti O, Herbrecht R et al.; Third European Conference on Infections in Leukemia. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: Dummary of the ECIL 3- 2009 update. Bone Marrow Transplant. 46(5), 709-718 (2011
29. Coukell AJ, Brogden RN. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis. Drugs 55(4), 585-612 (1998
30. Moen MD, Lyseng-Williamson KA, Scott LJ. Liposomal amphotericin B: A review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 69(3), 361-392 (2009
31. Eiden C, Peyrière H, Cociglio M et al.; Network of the French Pharmacovigilance Centers. Adverse effects of voriconazole: Analysis of the French Pharmacovigilance Database. Ann. Pharmacother. 41(5), 755-763 (2007
32. Metzke B, Neubauer WC, Hieke S, Jung M, Wäsch R, Engelhardt M. Use of systemic antifungals in daily clinical practice in the haematology and oncology setting: Results of a prospective observational analysis. Pharmacoepidemiol. Drug Saf. 21(9), 953-963 (2012
33. Jacobs F, Selleslag D, Aoun M, Sonet A, Gadisseur A. An observational efficacy and safety analysis of the treatment of acute invasive aspergillosis using voriconazole. Turner, Chen, Slavin & Kong www.expert-reviews.com31(6), 1173-1179 (2012
34. Jeu L, Piacenti FJ, Lyakhovetskiy AG, Fung HB. Voriconazole. Clin. Ther. 25(5), 1321-1381 (2003
35. Przepiorka D, Buadi FK, McClune B. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia. Pharmacotherapy 28(1), 58-63 (2008
36. Jørgensen K, Gøtzsche P, Johansen H. Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database of Syst. Rev. 1, CD004707 (2006
37. Dixon S, McKeen E, Tabberer M, Paisley S. Economic evaluations of treatments for systemic fungal infections: A systematic review of the literature. Pharmacoeconomics 22(7), 421-433 (2004
38. Playford EG, Lipman J, Sorrell TC. Prophylaxis, empirical and preemptive treatment of invasive candidiasis. Curr. Opin. Crit. Care 16(5), 470-474 (2010
39. Freemantle N, Tharmanathan P, Herbrecht R. Systematic review and mixed treatment comparison of randomized evidence for empirical, pre-emptive and directed treatment strategies for invasive mould disease. J. Antimicrob. Chemother. 66(Suppl. 1), i25-i35 (2011
40. Al-Badriyeh D, Liew D, Stewart K, Kong DC. Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia. J. Antimicrob. Chemother. 63(1), 197-208 (2009
41. Al-Badriyeh D, Liew D, Stewart K, Kong DC. Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia. J. Antimicrob. Chemother. 63(6), 1276-1285 (2009
42. Al-Badriyeh D, Liew D, Stewart K, Kong DC. Pharmacoeconomic analysis of voriconazole vs. caspofungin in the empirical antifungal therapy of febrile neutropenia in Australia. Mycoses 55(3), 244-256 (2012
43. Bruynesteyn K, Gant V, McKenzie C et al. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. Eur. J. Haematol. 78(6), 532-539 (2007
44. Collins CD, Stuntebeck ER, DePestel DD, Stevenson JG. Pharmacoeconomic analysis of liposomal amphotericin B versus voriconazole for empirical treatment of febrile neutropenia. Clin. Drug Investig. 27(4), 233-241 (2007
45. Kaskel P, Tuschy S, Wagner A et al. Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting. Ann. Hematol. 87(4), 311-319 (2008
46. Stam WB, Aversa F, Kumar RN, Jansen JP. Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy. Value Health 11(5), 830-841 (2008
47. Wingard JR, Leather HL, Wood CA et al. Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever. Am. J. Health. Syst. Pharm. 64(6), 637-643 (2007
48. Naik S, Lundberg J, Kumar R, Sjolin J, Jansen J. Economic evaluation of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden. Scand. J. Infect. Dis. 43(6-7), 504-514 (2011
49. Romá-Sánchez E, Poveda-Andrés JL, García-Pellicer J, Salavert-Lletí M, Jarque-Ramos I. Cost-effectiveness analysis of the empirical antifungal strategy in oncohaematological patients. Farm. Hosp. 32(1), 7-17 (2008
50. Shehab N, DePestel DD, Mackler ER, Collins CD, Welch K, Erba HP. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia. Pharmacotherapy 27(7), 970-979 (2007
51. Rubio-Terrés C, Grau S. Pharmacoeconomics of voriconazole. Expert Opin. Pharmacother. 11(6), 877-887 (2010
52. de Pauw BE, Sable CA, Walsh TJ et al. Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: Analysis of results from the Caspofungin Empirical Therapy Study. Transpl. Infect. Dis. 8(1), 31-37 (2006
53. Revicki DA, Lenderking WR. Methods and issues associated with the use of quality-adjusted life-years. Expert Rev. Pharmacoecon. Outcomes Res. 12(1), 105-114 (2012
54. Morrissey CO, Chen SC, Sorrell TC et al. Design issues in a randomized controlled trial of a pre-emptive versus empiric antifungal strategy for invasive aspergillosis in patients with high-risk hematologic malignancies. Leuk. Lymphoma 52(2), 179-193 (2011
55. van der Linden JW, Jansen RR, Bresters D et al. Azole-resistant central nervous system aspergillosis. Clin. Infect. Dis. 48(8), 1111-1113 (2009
56. Mikolajewska A, Schwartz S, Ruhnke M. Antifungal treatment strategies in patients with haematological diseases or cancer: From prophylaxis to empirical, pre-emptive and targeted therapy. Mycoses 55(1), 2-16 (2012
57. Ostrosky-Zeichner L, Casadevall A, Galgiani JN, Odds FC, Rex JH. An insight into the antifungal pipeline: Delected new molecules and beyond. Nat. Rev. Drug Discov. 9(9), 719-727 (2010
58. Rojas R, Molina JR, Jarque I et al. Outcome of antifungal combination therapy for invasive mold infections in hematological patients is independent of the chosen combination. Mediterr. J. Hematol. Infect. Dis. 4(1), e2012011 (2012
59. Baddley JW, Pappas PG. Antifungal combination therapy: Clinical potential. Drugs 65(11), 1461-1480 (2005
60. Marr K, Schlamm H, Rottinghaus S et al. A randomized, double-blind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis. Presented at: 22nd European Congress of Clinical Microbiology and Infectious Diseases. Congrex, Switzerland Ltd., London, UK, 31 March-3 April 2012